Compare CDW Corp. (CDW) vs Summit Therapeutics Inc (SMMT) Price & Performance

CDW trades at $135.79, down 0.47% on the day, with a bearish technical signal. The stock shows strong profitability with a 44.01% ROE and trades at a P/E of 16.27. Recent Q2 2026 earnings beat expectations with EPS of $2.91, driven by 10% revenue growth, though margin pressures were noted. Analyst consensus is bullish with a $148.67 price target. The company maintains a solid balance sheet with a debt-to-asset ratio of 39.8% as of 2024.

The outlook for CDW is positive due to AI and infrastructure demand, but margin compression and a CFO transition in 2027 pose risks. Upside potential exists if the company meets Q3 2026 EPS expectations of $2.91 and sustains revenue growth. Key risks include competitive pressures and macroeconomic volatility affecting IT spending.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.